This catapulted the drugs into the weight-loss market, with pharmaceutical companies developing higher-dosage versions for patients seeking to manage obesity
Performed on every batch to confirm the active ingredient is present at the labeled concentration
Users who switched from semaglutide to similar dual or triple agonists report better weight loss outcomes (15-25% versus 10-15%) and often lower nausea rates
If FDA does not place tirzepatide and semaglutide back on its shortage list, compounded copies will be fair game in court for Lilly and Novo, and companies like Hims and others selling them will need to need to prepare their litigation strategies and/or quickly find alternative products
Oral contraceptives present a unique interaction consideration with tirzepatide due to the potential for reduced absorption and efficacy
About 1 in 8 Americans have used injectable GLP-1 drugs, according to a survey from KFF, a nonprofit health policy research group